Roswell Park Cancer Institute: Colorectal Neoplasms trials

The registry lists 24 Colorectal Neoplasms studies with Roswell Park Cancer Institute as lead sponsor. 4 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 11Phase 2 13No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal CancerNot yet recruitingNCT07745023Not applicable
• Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal CancerRecruitingNCT06307548Phase 1/2
• Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT04511039Phase 1
• Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal MetastasesRecruitingNCT03965234Phase 1/2
• Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer ScreeningCompletedNCT04607291Phase 1Results posted
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyCompletedNCT04109924Phase 2Results posted
• Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the LiverCompletedNCT03403634Phase 2Results posted
• Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02713373Phase 1/2Results posted
• Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal CancerTerminatedNCT01545141Phase 1/2Results posted
• High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal CancerTerminatedNCT01198548Phase 2Results posted
• Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus IrinotecanTerminatedNCT01004159Phase 2Results posted
• Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal CancerTerminatedNCT00107315Phase 2Results posted
• Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)WithdrawnNCT05518032Phase 2
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2
• Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American CommunitiesCompletedNCT02100254Not applicable
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedNCT01522820Phase 1
• DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D SupplementsCompletedNCT00550563Not applicable
• Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal CancerCompletedNCT00096330Phase 1
• Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal CancerTerminatedNCT00087334Phase 1/2
• Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the RectumCompletedNCT00086931Phase 1/2
• Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal CancerCompletedNCT00084721Phase 1
• Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerCompletedNCT00040820Not applicable
• Diagnostic Procedure for Identifying Patients With Metastatic Colorectal CancerCompletedNCT00003186Not applicable